Financial Times Examines Intellectual Property Debate in India
May 16, 2013
The Financial Times examines how the "struggle of educated, middle-class patients to obtain cutting-edge medicine ... has led to a showdown between India and western pharmaceutical companies over the patents and prices of lifesaving drugs" in the country. The newspaper writes, "Western drugmakers fear India will inspire other emerging markets to challenge their patents," adding, "They have accused India of trampling on their intellectual property rights after a series of decisions overriding, revoking or refusing patents on cancer and hepatitis C drugs from Bayer, Pfizer, Roche and Novartis."
"At a recent U.S. congressional hearing, Roy Waldron, Pfizer's chief intellectual property officer, complained that New Delhi had 'routinely flouted trade rules to bolster the Indian generics industry,'" theView Full Article
India's Supreme Court Ruling on Drug Patent Will Promote Affordable Medicines, "Preserve" Innovation Incentives
Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)